Article
EZH2 inhibition mitigates HIV immune evasion, reduces reservoir formation, and promotes skewing of CD8+ T cells toward less-exhausted phenotypes.
Cell reports - 27 May 2025
Gramatica Andrea, Miller Itzayana G, Ward Adam R, Khan Farzana, Kemmer Tyler J, Weiler Jared, Huynh Tan Thinh, Zumbo Paul, Kurland Andrew P, Leyre Louise, Ren Yanqin, Klevorn Thais, Copertino Dennis C, Chukwukere Uchenna, Levinger Callie, Dilling Thomas R, Linden Noemi, Board Nathan L, Falling Iversen Emma, Terry Sandra, Mota Talia M, Bedir Seden, Clayton Kiera L, Bosque Alberto, MacLaren Ehui Lynsay, Kovacs Colin, Betel Doron, Johnson Jeffry R, Paiardini Mirko, Danesh Ali, Jones R Brad
Abstract excerpt
Persistent HIV reservoirs in CD4+ T cells pose a barrier to curing HIV infection. We identify overexpression of enhancer of zeste homolog 2 (EZH2) in HIV-infected CD4+ T cells that survive cytotoxic T lymphocyte (CTL) exposure, suggesting a mechanism of CTL resistance. Inhibition of EZH2 with the US Food and Drug Administration-approved drug tazemetostat increases surface expression of major histocompatibility...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.